HeartSciences (HSCS) Stock Price, News & Analysis

Company Overview

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Key Stats

• Today's Range: $3.57 to $3.88
• 50-Day Range: $3.26 to $4.49
• 52-Week Range: $2.36 to $5.30
• Volume: 45,548 shs
• Average Volume: 123,871 shs
• Market Capitalization: $3.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

HeartSciences Stock Analysis - MarketRank™

HeartSciences scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

HeartSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

HeartSciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for HeartSciences are expected to grow in the coming year, from ($10.01) to ($8.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of HeartSciences is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of HeartSciences is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

HeartSciences has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.07% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 167.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HeartSciences does not currently pay a dividend.

Dividend Growth

HeartSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.07% of the float of HeartSciences has been sold short.

Short Interest Ratio / Days to Cover

HeartSciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in HeartSciences has recently increased by 167.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for HeartSciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HeartSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of HeartSciences is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of HeartSciences is held by institutions.

HSCS Stock Analysis - Frequently Asked Questions

How have HSCS shares performed this year?

HeartSciences' stock was trading at $3.82 at the beginning of the year. Since then, HSCS stock has decreased by 3.8% and is now trading at $3.6750.

How were HeartSciences' earnings last quarter?

HeartSciences Inc. (NASDAQ:HSCS) issued its earnings results on Thursday, March, 13th. The company reported ($2.57) EPS for the quarter, missing analysts' consensus estimates of ($2.53) by $0.04.

When did HeartSciences' stock split?

HeartSciences's stock reverse split before market open on Friday, May 17th 2024.The 1-100 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did HeartSciences IPO?

HeartSciences (HSCS) raised $9 million in an IPO on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO.

How do I buy shares of HeartSciences?

Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HeartSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HeartSciences investors own include Meta Platforms (META), Cardio Diagnostics (CDIO), Invesco QQQ (QQQ), RH (RH), Exxon Mobil (XOM), Amarin (AMRN) and American Express (AXP).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSCS
• CIK: 1468492
• Web: heartsciences.com
• Phone: 682-237-7781
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +253.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.61 million
• Net Margins: N/A
• Pretax Margin: -50,833.34%
• Return on Equity: -178.80%
• Return on Assets: -109.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 198.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.16 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 1,080,000
• Free Float: 1,062,000
• Market Cap: $3.97 million
• Optionable: Not Optionable
• Beta: 2.57